DOCSLIB.ORG

Table S2: Differentially Expressed Genes in Monocytes from SJIA

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Table S2: Differentially Expressed Genes in Monocytes from SJIA BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis Table S2: Differentially expressed genes in monocytes from SJIA patients with high ferritin vs normal ferritin ENTREZID logFC AveExpr t P.Value adj.P.Val MS4A4A 51338 2.190196 4.244735 8.4317 3.03E-10 3.93E-06 FCGR1A 2209 1.832626 5.191407 7.732826 2.31E-09 1.39E-05 WASF1 8936 2.152067 1.43915 7.530783 3.69E-09 1.39E-05 FAM20A 54757 2.474761 3.578268 7.632571 4.28E-09 1.39E-05 CLU 1191 4.534403 3.843633 7.551856 1.07E-08 2.77E-05 SMAD1 4086 1.268278 3.507093 6.633495 6.40E-08 0.000138 FZD5 7855 1.246973 2.879759 6.517221 9.29E-08 0.000145 PIM1 5292 1.271881 3.884803 6.508848 9.54E-08 0.000145 FPR2 2358 1.360192 5.004079 6.499801 1.01E-07 0.000145 ARID5B 84159 1.890049 3.750909 6.490162 1.20E-07 0.000156 SOCS3 9021 2.310428 2.737279 6.495284 1.35E-07 0.000159 FCGR1B 2210 1.694497 5.154892 6.217976 3.03E-07 0.000328 DACH1 1602 1.539506 1.506071 6.065837 3.97E-07 0.000396 CACNA2D3 55799 -1.92407 4.213692 -6.06965 4.68E-07 0.000434 FPR1 2357 1.209795 7.192649 5.940801 6.01E-07 0.000517 SH3PXD2A 9644 -1.03401 4.074356 -5.91559 6.44E-07 0.000517 SQOR 58472 0.73375 5.969033 5.896744 6.84E-07 0.000517 MCTP2 55784 1.896449 5.61473 5.983647 7.18E-07 0.000517 DYSF 8291 1.544211 6.388747 5.865596 8.90E-07 0.000607 DSC2 1824 1.764703 5.047865 5.83971 1.08E-06 0.000703 STON2 85439 -1.29121 3.458252 -5.70943 1.25E-06 0.000733 GCNT1 2650 0.852763 4.966676 5.691336 1.33E-06 0.000733 CFL1 1072 0.851705 5.97814 5.678738 1.38E-06 0.000733 GNG10 2790 1.107621 4.812675 5.663033 1.45E-06 0.000733 ZNF175 7728 -0.93175 4.073791 -5.65353 1.50E-06 0.000733 UBE3D 90025 -1.03666 2.62462 -5.64905 1.52E-06 0.000733 SMC2 10592 -0.98014 3.854468 -5.64761 1.53E-06 0.000733 CD81 975 1.02684 2.9974 5.634939 1.59E-06 0.000735 LIMK2 3985 1.081223 5.000122 5.624567 1.64E-06 0.000735 CPT1A 1374 0.907861 5.610705 5.589689 1.84E-06 0.000791 GM2A 2760 0.864216 6.76521 5.565654 1.99E-06 0.000791 GPR84 53831 1.528135 2.378117 5.568409 1.99E-06 0.000791 POMP 51371 0.836364 4.855967 5.561759 2.01E-06 0.000791 ORMDL2 29095 0.938696 4.604043 5.549501 2.09E-06 0.000798 F5 2153 0.878972 6.963642 5.519477 2.30E-06 0.000854 ACAD11 84129 -0.7953 3.702708 -5.5014 2.44E-06 0.00088 PLAC8 51316 1.679132 5.792997 5.562184 2.58E-06 0.000905 CD82 3732 0.961846 3.508497 5.433299 3.04E-06 0.001011 CD1E 913 -2.20953 1.335264 -5.43976 3.04E-06 0.001011 SLC39A8 64116 1.712669 3.175458 5.456354 3.21E-06 0.001021 TMEM167A 153339 0.749058 6.89511 5.414435 3.23E-06 0.001021 PAN2 9924 -0.58892 5.233771 -5.39184 3.47E-06 0.001072 LITAF 9516 1.222942 6.265017 5.377836 3.85E-06 0.001161 BLOC1S1 2647 1.101181 3.08831 5.352263 3.94E-06 0.001161 F2RL2 2151 -1.08761 3.63738 -5.34442 4.04E-06 0.001164 Schulert GS, et al. Ann Rheum Dis 2021; 80:617–625. doi: 10.1136/annrheumdis-2020-217470 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis FAM129A 116496 0.933794 6.750819 5.336332 4.15E-06 0.001169 TMED8 283578 0.563176 5.937928 5.302766 4.62E-06 0.001274 DNAJC15 29103 1.051614 5.643874 5.273667 5.08E-06 0.001373 TPST2 8459 0.881668 5.294534 5.258252 5.32E-06 0.001409 RHOU 58480 0.871794 5.003252 5.229954 5.83E-06 0.001511 CR1 1378 1.115447 7.179779 5.17101 7.23E-06 0.001733 VAMP5 10791 1.215261 3.075069 5.164022 7.34E-06 0.001733 MT2A 4502 1.533108 2.926509 5.190953 7.47E-06 0.001733 TIFA 92610 1.049307 4.001225 5.152155 7.47E-06 0.001733 R3HDM4 91300 1.002544 3.518205 5.146712 7.60E-06 0.001733 KREMEN1 83999 0.886133 4.166079 5.146043 7.61E-06 0.001733 NEMP1 23306 -1.03939 3.564945 -5.14598 7.62E-06 0.001733 AQP9 366 1.735848 5.858342 5.215323 7.99E-06 0.001787 STOM 2040 0.882168 5.872767 5.116898 8.36E-06 0.001837 UBAP1 51271 0.634887 5.184932 5.11152 8.50E-06 0.001837 B4GALT5 9334 0.921163 6.428555 5.093532 9.00E-06 0.001914 CTSA 5476 0.919311 7.341106 5.080355 9.39E-06 0.001963 PTPDC1 138639 -1.36549 1.640829 -5.06876 9.74E-06 0.001968 PRPS2 5634 0.724368 3.55328 5.067444 9.78E-06 0.001968 CCDC14 64770 -0.86784 4.937713 -5.06474 9.86E-06 0.001968 PRRG4 79056 0.553566 5.060522 5.052141 1.03E-05 0.001974 TNNT1 7138 1.722227 1.722191 5.069485 1.03E-05 0.001974 GYG1 2992 0.556925 5.371168 5.049305 1.04E-05 0.001974 GMFG 9535 0.699049 6.36054 5.042922 1.06E-05 0.001974 IFITM2 10581 1.869608 6.767794 5.135646 1.07E-05 0.001974 RBFA 79863 -0.86711 2.585778 -5.03525 1.08E-05 0.001979 TMEM127 55654 0.7228 7.12166 5.026114 1.12E-05 0.002008 CD63 967 1.161541 6.641661 5.039156 1.13E-05 0.002008 JAK3 3718 1.071233 5.456367 5.016692 1.18E-05 0.00204 BASP1 10409 1.277944 5.406056 5.036456 1.18E-05 0.00204 TMBIM6 7009 0.629772 8.182448 5.002579 1.20E-05 0.00205 LILRA6 79168 0.868465 6.919574 4.995195 1.23E-05 0.00205 IMPA2 3613 0.684781 4.92483 4.994465 1.23E-05 0.00205 RAB8B 51762 0.788068 6.208799 4.986434 1.26E-05 0.002056 KAT2A 2648 -1.03304 2.878202 -4.98338 1.28E-05 0.002056 UBA5 79876 -0.7562 4.054101 -4.98172 1.28E-05 0.002056 IGF2BP3 10643 1.43472 3.059351 4.980855 1.35E-05 0.002134 H2AFJ 55766 1.094605 3.355427 4.96234 1.37E-05 0.002134 CHCHD7 79145 0.8274 5.086581 4.954776 1.40E-05 0.002148 TARBP1 6894 -0.85294 4.873378 -4.95227 1.41E-05 0.002148 ST14 6768 1.270406 3.340502 4.963409 1.42E-05 0.002148 SMPDL3A 10924 0.853486 3.37267 4.940909 1.46E-05 0.00216 ZMYND11 10771 -0.75582 4.031209 -4.93998 1.47E-05 0.00216 VWA5A 4013 1.051467 3.34311 4.936394 1.48E-05 0.00216 MT1X 4501 1.31619 2.052842 4.928442 1.52E-05 0.002178 CXCL16 58191 0.955675 5.388337 4.926836 1.53E-05 0.002178 UBE2L3 7332 0.57562 5.130905 4.920006 1.56E-05 0.002193 Schulert GS, et al. Ann Rheum Dis 2021; 80:617–625. doi: 10.1136/annrheumdis-2020-217470 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis CTNND1 1500 -0.66665 6.877517 -4.91775 1.57E-05 0.002193 MGST3 4259 0.691213 5.770989 4.912856 1.60E-05 0.002204 UBE2J1 51465 0.934295 6.235453 4.896049 1.68E-05 0.002299 ZNF589 51385 -0.68874 4.629289 -4.89282 1.70E-05 0.002299 KANK2 25959 -0.56629 3.95006 -4.87811 1.78E-05 0.002358 RSAD1 55316 -0.81287 3.809714 -4.87599 1.79E-05 0.002358 NDUFB9 4715 0.715062 5.477529 4.875034 1.80E-05 0.002358 PPP1R3B 79660 0.869002 4.489008 4.865309 1.86E-05 0.002407 ZNF736 728927 -0.65624 4.983984 -4.86055 1.88E-05 0.00242 CDK5RAP2 55755 -0.85141 4.863029 -4.84835 1.96E-05 0.00249 BCL2A1 597 1.309598 4.123117 4.860376 2.07E-05 0.002597 CLEC2D 29121 -0.9064 5.64618 -4.82892 2.08E-05 0.002597 TAF4B 6875 -1.47777 1.439848 -4.8206 2.14E-05 0.002637 ALDH1A1 216 -1.58705 6.384964 -4.88851 2.15E-05 0.002637 FCGR3A 2214 1.411295 6.324651 4.859069 2.20E-05 0.002655 FLVCR2 55640 0.943766 4.743243 4.807768 2.23E-05 0.002655 ACSL1 2180 1.063163 7.070704 4.815908 2.24E-05 0.002655 MTR 4548 -0.48 5.943447 -4.80402 2.25E-05 0.002655 LOC10099671.01E+08 -1.25676 3.534469 -4.79898 2.29E-05 0.002674 ACAA2 10449 0.657251 6.012664 4.771006 2.50E-05 0.002894 S100A9 6280 1.277946 8.08226 4.788976 2.59E-05 0.002947 DERL1 79139 0.512209 5.818377 4.759603 2.59E-05 0.002947 C1ORF228 339541 0.762018 2.441595 4.753988 2.64E-05 0.002973 ELMO2 63916 0.667265 5.695467 4.738732 2.77E-05 0.003093 RAB1B 81876 0.844596 4.422059 4.708019 3.05E-05 0.003377 ZNHIT1 10467 0.652154 5.383766 4.70184 3.11E-05 0.003414 TNFSF8 944 -0.86705 5.534343 -4.69881 3.14E-05 0.003417 UBE2F 140739 0.46135 4.551357 4.694985 3.17E-05 0.00343 RAB13 5872 0.774534 4.311582 4.671621 3.41E-05 0.00366 C6ORF89 221477 0.462461 5.447402 4.657177 3.57E-05 0.003755 CAPZB 832 0.589863 5.647883 4.656595 3.58E-05 0.003755 AFF3 3899 -0.84919 4.125988 -4.65563 3.59E-05 0.003755 CLIC1 1192 0.768367 7.130546 4.653058 3.62E-05 0.003755 SLC2A3 6515 1.007611 6.68736 4.648538 3.76E-05 0.003872 MCEMP1 199675 1.404853 5.951082 4.681543 3.85E-05 0.003936 S100A8 6279 1.380916 9.570264 4.657299 4.08E-05 0.004132 GNG5 2787 0.838863 5.254902 4.610478 4.13E-05 0.004157 PDE4DIP 9659 -0.7558 6.583324 -4.60504 4.21E-05 0.004171 IGFBP7 3490 0.848944 4.135958 4.604442 4.21E-05 0.004171 WBP2 23558 0.68723 5.050039 4.600678 4.26E-05 0.004188 IFITM1 8519 2.462037 2.411347 4.701092 4.30E-05 0.004196 DBI 1622 0.861863 4.731628 4.594297 4.35E-05 0.004209 GPR135 64582 -1.03125 1.978208 -4.59076 4.40E-05 0.004224 NCAPG2 54892 -0.91638 2.615493 -4.58737 4.44E-05 0.004238 EMB 133418 0.655008 7.049032 4.578224 4.57E-05 0.004301 ZNF223 7766 -0.83406 2.200936 -4.57795 4.58E-05 0.004301 PCDH12 51294 -1.10161 2.708648 -4.55547 4.91E-05 0.00458 Schulert GS, et al.
Load more

Recommended publications
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Tranexamic Acid Inhibits the Plasma and Non-Irradiated Skin Markers Of
    Biomedicine & Pharmacotherapy 107 (2018) 54–58 Contents lists available at ScienceDirect Biomedicine & Pharmacotherapy journal homepage: www.elsevier.com/locate/biopha Original Article Tranexamic acid inhibits the plasma and non-irradiated skin markers of photoaging induced by long-term UVA eye irradiation in female mice T ⁎ Keiichi Hiramotoa, , Yurika Yamatea, Daijiro Sugiyamab, Kazunari Matsudab, Yasutaka Iizukab, Tomohiko Yamaguchib a Department of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minamitamagakicho, Suzuka, Mie, 513-8670, Japan b R&D Department, Daiichi Sankyo Healthcare Co., LTD., 3-14-10 Nihonbashi, Chuo-ku, Tokyo, 103-8234, Japan ARTICLE INFO ABSTRACT Keywords: Photoaging can be induced by long-term ultraviolet (UV)A eye irradiation, but an ameliorating method for such Tranexamic acid photoaging is not known. In this study, we examined the effects of tranexamic acid (trans-4-aminomethylcy- Photoaging clohexanecarboxylic acid) on photoaging of the skin induced by UVA eye irradiation. We used the C57BL/6 j Urocortin 2 female mice and locally exposed their eyes to UVA at a dose of 110 kJ/m2 using an FL20SBLB-A lamp multiple β-Endorphin times a week for one year. The plasma urocortin 2, β-endorphin, methionine enkephalin (OGF), and histamine Methionine encephalin content, as well as the expression of the corticotropin-releasing hormone receptor (CRHR) type 2, μ-opioid Histamine Estrogen receptor-β receptor, opioid growth factor receptor (OGFR), T-bet, and GATA3 increased in the mice subjected to UVA eye irradiation. However, the increased levels of urocortin 2, methionine enkephalin, histamine, OGFR, T-bet, and GATA3 were suppressed by tranexamic acid treatment.
    [Show full text]
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6 Dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-Cell Lymphoma
    BCL6 suppresses an IL10RA/JAK2/STAT3 pathway Synthetic lethal screen demonstrates that a JAK2 inhibitor suppresses a BCL6 dependent IL10RA/JAK2/STAT3 pathway in high grade B-cell lymphoma. Daniel Beck1,6, Jenny Zobel3,6, Ruth Barber1,2,6, Sian Evans1, Larissa Lezina1, Rebecca L. Allchin1, Matthew Blades4, Richard Elliott5, Christopher J. Lord5, Alan Ashworth5, Andrew C.G. Porter3, Simon D. Wagner1 1Department of Cancer Studies, Ernest and Helen Scott Haematology Research Institute and, 2 Leicester Diagnostic and Drug Development (LD3) Centre, University of Leicester, Lancaster Road, Leicester LE1 7HB, UK, 3Department of Haematology, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0NN, UK. 4Bioinformatics and Biostatistics Analysis Support Hub (B/BASH), University of Leicester, Lancaster Road, Leicester LE1 9HN and 5The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK. 6The first three authors contributed equally to this work Running title: BCL6 suppresses an IL10RA/JAK2/STAT3 pathway. To whom correspondence should be addressed: Simon D. Wagner, Department of Cancer Studies, Room 104, Hodgkin Building, University of Leicester, Lancaster Road, Leicester LE1 7HB, UK. Tel: 0441162525584, Fax: 0441162525616, Email: [email protected] Keywords: cancer therapy, Janus kinase (JAK), lymphocyte, lymphoma, transcription factor, B-cell lymphoma 6 (BCL-6), synthetic lethal screen. ABSTRACT which shows higher levels of IL10RA, JAK2 and We demonstrate the usefulness of synthetic lethal STAT3 but lower levels of BCL6 than GC- screening of a conditionally BCL6 deficient DLBCL and might be usefully combined with Burkitt lymphoma cell line, DG75-AB7, with a novel approaches such as inhibition of IL10RA.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Supplementary Material
    BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Page 1 / 45 SUPPLEMENTARY MATERIAL Appendix A1: Neuropsychological protocol. Appendix A2: Description of the four cases at the transitional stage. Table A1: Clinical status and center proportion in each batch. Table A2: Complete output from EdgeR. Table A3: List of the putative target genes. Table A4: Complete output from DIANA-miRPath v.3. Table A5: Comparison of studies investigating miRNAs from brain samples. Figure A1: Stratified nested cross-validation. Figure A2: Expression heatmap of miRNA signature. Figure A3: Bootstrapped ROC AUC scores. Figure A4: ROC AUC scores with 100 different fold splits. Figure A5: Presymptomatic subjects probability scores. Figure A6: Heatmap of the level of enrichment in KEGG pathways. Kmetzsch V, et al. J Neurol Neurosurg Psychiatry 2021; 92:485–493. doi: 10.1136/jnnp-2020-324647 BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) J Neurol Neurosurg Psychiatry Appendix A1. Neuropsychological protocol The PREV-DEMALS cognitive evaluation included standardized neuropsychological tests to investigate all cognitive domains, and in particular frontal lobe functions. The scores were provided previously (Bertrand et al., 2018). Briefly, global cognitive efficiency was evaluated by means of Mini-Mental State Examination (MMSE) and Mattis Dementia Rating Scale (MDRS). Frontal executive functions were assessed with Frontal Assessment Battery (FAB), forward and backward digit spans, Trail Making Test part A and B (TMT-A and TMT-B), Wisconsin Card Sorting Test (WCST), and Symbol-Digit Modalities test.
    [Show full text]
  • Tpit (TBX19) (NM 005149) Human Recombinant Protein Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP310787 Tpit (TBX19) (NM_005149) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human T-box 19 (TBX19) Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 48.1 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Bioactivity: ELISpot (PMID: 30008158) Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_005140 Locus ID: 9095 UniProt ID: O60806, B3KRD9 RefSeq Size: 2882 Cytogenetics: 1q24.2 RefSeq ORF: 1344 Synonyms: dJ747L4.1; TBS19; TPIT This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 Tpit (TBX19) (NM_005149) Human Recombinant Protein – TP310787 Summary: This gene is a member of a phylogenetically conserved family of genes that share a common DNA-binding domain, the T-box. T-box genes encode transcription factors involved in the regulation of developmental processes. Mutations in this gene were found in patients with isolated deficiency of pituitary POMC-derived ACTH, suggesting an essential role for this gene in differentiation of the pituitary POMC lineage.
    [Show full text]
  • Genome-Wide DNA Methylation Profiling Reveals Methylation Markers
    Author Manuscript Published OnlineFirst on January 24, 2017; DOI: 10.1158/1078-0432.CCR-16-2641 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Genome-wide DNA methylation profiling reveals methylation markers 2 associated with 3q gain for detection of cervical pre-cancer and cancer 3 4 Wina Verlaat1, Peter J.F. Snijders1, Putri W. Novianti1,2, Saskia M. Wilting1, Lise M.A. De Strooper1, 5 Geert Trooskens3,Johan Vandersmissen3, Wim Van Criekinge3, G. Bea A. Wisman4, Chris J.L.M. 6 Meijer1, Daniëlle A.M. Heideman1, Renske D.M. Steenbergen1 * 7 8 1Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands 9 2Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The 10 Netherlands 11 3Department of Mathematical Modeling, Statistics and Bioinformatics, Ghent University, Ghent, 12 Belgium. 13 4Department of Gynecologic Oncology, Cancer Research Center Groningen, University of Groningen, 14 University Medical Center Groningen, Groningen, The Netherlands 15 16 Running title: 17 Methylation markers at 3q for cervical pre(cancer) detection 18 19 Key words: 20 Methyl Binding Domain/MBD-Seq, epigenetics, copy number aberrations, cervical carcinogenesis, 21 biomarkers 22 23 Additional information: 24 * Corresponding author: 25 Renske D.M. Steenbergen, PhD, Department of Pathology, VU University Medical Center, PO Box 26 7057, 1007 MB Amsterdam; The Netherlands, E-mail: [email protected] 27 28 Financial support: 29 This study was sponsored by Eurostars E!6679 Cervix-care and the European Research Council (ERC 30 advanced 2012- AdG, proposal 322986; Mass-Care). The sources of funding did not have any 31 influence on the design of the study, collection, analysis and interpretation of the data and in writing 32 the manuscript.
    [Show full text]
  • Investigation Into the Effect of LRRK2-Rab10 Protein Interactions on the Proboscis Extension Response of the Fruit Fly Drosophila Melanogaster
    Investigation into the effect of LRRK2-Rab10 protein interactions on the Proboscis Extension Response of the fruit fly Drosophila melanogaster Laura Covill Masters by Research University of York Biology December 2018 Abstract Parkinson’s Disease (PD) is a debilitating disease which affects 1% of the population worldwide and is characterised by stiffness, tremor and bradykinesia. PD is a complex disease with many suspected genetic and environmental causes, and it is critical to understand all the pathways involved in disease progression to develop effective therapies for PD, which currently has no cure. A kinase- coding gene, LRRK2 has emerged as a focal point for much PD research, particularly PD-associated SNP LRRK2-G2019S, which leads to LRRK2 overactivity. Rab proteins, a series of small GTPases, have been identified among the proteins phosphorylated by LRRK2. These interactions may be modelled in the fruit fly Drosophila melanogaster. Using optogenetics in the fly, this project investigates the relationship between the LRRK2-G2019S and Rab10 interaction, and the speed and degree of tremor of Proboscis Extension Response (PER) by triggering a PER in fly lines of different genotypes. Significant bradykinesia in Rab10 null flies which was not recreated in flies with dopaminergic neuron Rab10RNAi suggests that the bradykinesia PER phenotype is caused by off-target effect of Rab10-KO in another tissue of the fly than the dopaminergic neurons. Over-expression of Rab10 in dopaminergic neurons of flies also expressing LRRK2-G2019S produced
    [Show full text]
  • CHML Promotes Liver Cancer Metastasis by Facilitating Rab14 Recycle
    ARTICLE https://doi.org/10.1038/s41467-019-10364-0 OPEN CHML promotes liver cancer metastasis by facilitating Rab14 recycle Tian-Wei Chen1,2,3, Fen-Fen Yin1,2, Yan-Mei Yuan1,2, Dong-Xian Guan1, Erbin Zhang1,2, Feng-Kun Zhang1,2, Hao Jiang1,2, Ning Ma1,2, Jing-Jing Wang1, Qian-Zhi Ni1,2, Lin Qiu1, Jing Feng3, Xue-Li Zhang3, Ying Bao4, Kang Wang5, Shu-Qun Cheng5, Xiao-Fan Wang6, Xiang Wang7, Jing-Jing Li1,2 & Dong Xie1,2,8,9 Metastasis-associated recurrence is the major cause of poor prognosis in hepatocellular 1234567890():,; carcinoma (HCC), however, the underlying mechanisms remain largely elusive. In this study, we report that expression of choroideremia-like (CHML) is increased in HCC, associated with poor survival, early recurrence and more satellite nodules in HCC patients. CHML promotes migration, invasion and metastasis of HCC cells, in a Rab14-dependent manner. Mechanism study reveals that CHML facilitates constant recycling of Rab14 by escorting Rab14 to the membrane. Furthermore, we identify several metastasis regulators as cargoes carried by Rab14-positive vesicles, including Mucin13 and CD44, which may contribute to metastasis- promoting effects of CHML. Altogether, our data establish CHML as a potential promoter of HCC metastasis, and the CHML-Rab14 axis may be a promising therapeutic target for HCC. 1 CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Xuhui district 200031, China. 2 University of Chinese Academy of Sciences, Chinese Academy of Sciences, Xuhui district 200031, China. 3 Department of General Surgery, Fengxian Hospital Affiliated to Southern Medical University, 6600 Nanfeng Road, Shanghai 201499, China.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]